Clinical Trial Update: Generation of Reactive T Cells Based on Tumor Whole Cell Antigen Nanovaccines

View source ↗

Summary

A registry entry describing a trial testing a tumor whole cell antigen nanovaccine to generate reactive T cells for non-small cell lung cancer; currently active…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tumor whole cell antigen nanovaccine

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Lung Cancer (NSCLC) | Status: ACTIVE_NOT_RECRUITING